Navigating the Frontier of Hematologic Malignancy Therapies. Series of 5 Modules

Program Overview

This activity will cover the latest advances in the therapeutic management of hematologic malignancies, including bispecific antibodies, CAR-T products, proteolysis-targeting chimeras, and antibody-drug conjugates — with an emphasis on novel targets and approaches. The prognostic role of circulating tumor DNA is also explored.

3.00 CE Credit(s)

Expires: March 12, 2024

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Analyze available data on bispecific antibodies for the treatment of multiple myeloma (Module 1 CME 0.5 credit)
Identify potential T-cell immunotherapeutic strategies for the treatment of lymphomas and other hematologic malignancies (Module 2 CME 0.5 credits)
Describe emerging proteolysis targeting chimeras (PROTACs) under investigation for the treatment of hematologic malignancies (Module 3 CME 0.5 credits)
Assess key data sets and ongoing clinical trials investigating antibody-drug conjugates for the treatment of acute myeloid leukemia (AML) (Module 4 CME: 0.5 credits)
Examine the potential utility of circulating tumor DNA for risk prediction and individualizing therapy for diffuse large B-cell lymphoma (DLBCL) (Module 5 CME: 1.0 credit)

Activity Faculty

Helen E. Heslop, MD, DSc (Hon) (Chair)

Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX

Saad Z. Usmani, MD, MBA, FACP

Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Katherine Donovan, PhD

Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Soheil Meshinchi, MD, PhD

Full Member, Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA

Mark Roschewski, MD

Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Provider Statement

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Supporter Statement

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

Featured RMEI CE Activities